Advertisement

Chemoprevention in Oral Cancer

  • Jeffrey Y. Tsai
  • Jasjit K. DillonEmail author
Chapter

Abstract

Though many agents have been identified as potential chemoprevention strategies against oral cancer, the availability of high-quality evidence supporting their use in clinical practice remains limited. In this chapter, we discuss the concept of chemoprevention of oral cancer, review the evidence of several chemoprevention agents that have undergone clinical studies, and conclude with the challenges that prevent the use of these agents in general clinical practice. We suggest that molecular identification of markers that can be measured and can correlate with disease risk and progression may aid in selecting high-risk populations and therapeutics suitable for future clinical investigation.

Keywords

Chemoprevention Oral cancer Oral premalignant lesions Oral leukoplakia Head and neck cancer N-acetylcysteine Bleomycin Polyphenols Retinoids Carotenoids COX-2 inhibitors PPAR-γ ligands Erlotinib Loss of heterozygosity Biomarkers 

References

  1. 1.
    Fotedar V, Fotedar S, Seam RK, Gupta MK. Oral cancer and chemoprevention. Int J Pharm Sci Invent. 2013;2(2):16–20.Google Scholar
  2. 2.
    Chau L, Jabra JT, Lai W, et al. Topical agents for oral cancer chemoprevention: a systematic review of the literature. Oral Oncol. 2017;67:153–9.CrossRefGoogle Scholar
  3. 3.
    Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990;323(12):795–801.CrossRefGoogle Scholar
  4. 4.
    Leoncini E, Nedovic D, Panic N, et al. Carotenoid intake from natural sources and head and neck cancer: a systematic review and meta-analysis of epidemiological studies. Cancer Epidemiol Biomark Prev. 2015;24(7):1003–11.CrossRefGoogle Scholar
  5. 5.
    Wilson JC, Murray LJ, Hughes CM, et al. Non-steroidal anti-inflammatory drug and aspirin use and the risk of head and neck cancer. Br J Cancer. 2013;108:1178–81.CrossRefGoogle Scholar
  6. 6.
    Bauman JE, Grandis J. Oral cancer chemoprevention – the end of EPOC, the beginning of an epoch of molecular selection. JAMA Oncol. 2016;2(2):178–9.CrossRefGoogle Scholar
  7. 7.
    William W, Papadimitrakopoulou V, Lee JJ, et al. Erlotinib and the risk of oral cancer: the erlotinib prevention of oral cancer (EPOC) randomized clinical trial. JAMA Oncol. 2016;2(2):209–16.CrossRefGoogle Scholar
  8. 8.
    Bhattacharya S. Natural antimutagens: a review. Res J Med Plant. 2011;5(2):116–26.CrossRefGoogle Scholar
  9. 9.
    Millea PJ. N-Acetylcysteine: multiple clinical applications. Am Fam Physician. 2009;80(3):265–9.PubMedGoogle Scholar
  10. 10.
    Lee MF, Chan CY, Hung HC, et al. N-acetylcysteine (NAC) inhibits cell growth by mediating the EGFR/Akt/HMG box-containing protein 1 (HBP1) signaling pathway in invasive oral cancer. Oral Oncol. 2013;49:129–35.CrossRefGoogle Scholar
  11. 11.
    Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol. 2007;25(16):2164–70.CrossRefGoogle Scholar
  12. 12.
    van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. J Natl Cancer Inst. 2000;92(12):977–86.CrossRefGoogle Scholar
  13. 13.
    Surber C, Elsner P, Farage MA. Topical applications and the mucosa. Curr Probl Dermatol. 2011;40:71–82.CrossRefGoogle Scholar
  14. 14.
    Epstein JB, Wong FL, Millner A, Le ND. Topical bleomycin treatment of oral leukoplakia: a randomized double-blind clinical trial. Head Neck. 1994;16(6):539–44.CrossRefGoogle Scholar
  15. 15.
    Ding Y, Yao H, Yao Y, et al. Protection of dietary polyphenols against oral cancer. Nutrients. 2013;5:2173–91.CrossRefGoogle Scholar
  16. 16.
    Gomes de Moura CF, Noguti J, Pacheco de Jesus GP, et al. Polyphenols as chemopreventive agent in oral carcinogenesis: putative mechanisms of action using in-vitro and in-vivo test systems. Eur J Cancer Prev. 2013;22:467–72.CrossRefGoogle Scholar
  17. 17.
    Tsao AS, Liu D, Martin J, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009;2(11):931–41.CrossRefGoogle Scholar
  18. 18.
    Rai B, Kaur J, Jacobs R, Singh J. Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress. J Oral Sci. 2010;52(2):251–6.CrossRefGoogle Scholar
  19. 19.
    Patel JB, Shah FD, Joshi GM, Patel PS. Clinical significance of inflammatory mediators in the pathogenesis of oral cancer. J Can Res Ther. 2016;12:447–57.CrossRefGoogle Scholar
  20. 20.
    Sheth SH, Johnson DE, Kensler TW, Bauman JE. Chemoprevention targets for tobacco-related head and neck cancer: past lessons and future directions. Oral Oncol. 2015;51:557–64.CrossRefGoogle Scholar
  21. 21.
    Foy JP, Bertolus C, William W, Saintigny P. Oral premalignancy: The roles of early detection and chemoprevention otolaryngol. Clin North Am. 2013;46(4):579–97.Google Scholar
  22. 22.
    Koch HF. Biochemical treatment of precancerous oral lesions: the effectiveness of various analogues of retinoic acid. J Maxillofac Surg. 1978;6:59–63.CrossRefGoogle Scholar
  23. 23.
    Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986;315(24):1501–5.CrossRefGoogle Scholar
  24. 24.
    Khuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006;98(7):441–50.CrossRefGoogle Scholar
  25. 25.
    Kadakia S, Badhey A, Milam M, et al. Topical oral cavity chemoprophylaxis using isotretinoin rinse: a 15-year experience. Laryngoscope. 2017;127:1595–9.CrossRefGoogle Scholar
  26. 26.
    Potter JD. The failure of cancer chemoprevention. Carcinogenesis. 2014;35(5):974–82.CrossRefGoogle Scholar
  27. 27.
    Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention systematic review and meta-analysis. JAMA. 2007;297(8):842–57.CrossRefGoogle Scholar
  28. 28.
    Lu R, Dan H, Wu R, et al. Lycopene: features and potential significance in the oral cancer and precancerous lesions. J Oral Pathol Med. 2011;40:361–8.CrossRefGoogle Scholar
  29. 29.
    Lin DT, Subbaramaiah K, Shah JP, et al. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck. 2002;24:792–9.CrossRefGoogle Scholar
  30. 30.
    Shi J, Leng W, Zhao L, et al. Nonsteroidal anti-inflammatory drugs using and risk of head and neck cancer: a dose–response meta analysis of prospective cohort studies. Oncotarget. 2017;8(58):99066–74.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Mushine JL, Atkinson JC, Greer RO, et al. Randomized, double-blind, placebo-controlled phase IIB trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res. 2004;10:1565–73.CrossRefGoogle Scholar
  32. 32.
    Papadimitrakopoulou VA, William W, Dannenberg AJ, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res. 2008;14(7):2095–101.CrossRefGoogle Scholar
  33. 33.
    Bertagnolli MM. Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. Lancet Oncol. 2007;8:439–43.CrossRefGoogle Scholar
  34. 34.
    Burotto M, Szabo E. PPARγ in head and neck cancer prevention. Oral Oncol. 2014;50(10):924–9.CrossRefGoogle Scholar
  35. 35.
    Govindarajan R, Siegel ER. The effect of exposure to thiazolidinediones on the development of head-and-neck cancer in patients with diabetes mellitus. Transl Res Oral Oncol. 2017;2:1–5.Google Scholar
  36. 36.
    Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res. 2000;6:357–62.PubMedGoogle Scholar
  37. 37.
    Bhatia A, Burtness B. Novel molecular targets for chemoprevention in malignancies of the head and neck. Cancers. 2017;9:113.CrossRefGoogle Scholar
  38. 38.
    Lodi G, Franchini R, Warnakulasuriya S, et al. Interventions for treating oral leukoplakia to prevent oral cancer. Cochrane Database Syst Rev. 2016;7:Art. No.: CD001829.Google Scholar
  39. 39.
    Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Alternat Compl Med. 2003;9(1):161–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Oral and Maxillofacial SurgeryUniversity of WashingtonSeattleUSA

Personalised recommendations